Free tool
FAERS Monitor: Heparin Sodium
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 201370 or its brand name (Heparin Sodium, Heparin Sodium). Reports on generic versions are filed under their own applications.
Reports
14,058
Serious
11,053
79% of reports
Hospitalization
5,586
Death reported
2,653
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- heparin-induced thrombocytopenia1,293
- drug ineffective1,043
- off label use787
- nausea754
- drug hypersensitivity643
- vomiting620
- hypotension571
- dyspnoea558
- pulmonary embolism519
- sepsis503
- pyrexia499
- anaemia488
- abdominal pain483
- thrombocytopenia479
- thrombosis458
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 464 |
| 2005 | 225 |
| 2006 | 189 |
| 2007 | 127 |
| 2008 | 1,029 |
| 2009 | 247 |
| 2010 | 472 |
| 2011 | 403 |
| 2012 | 356 |
| 2013 | 329 |
| 2014 | 276 |
| 2015 | 367 |
| 2016 | 402 |
| 2017 | 527 |
| 2018 | 642 |
| 2019 | 796 |
| 2020 | 705 |
| 2021 | 975 |
| 2022 | 1,141 |
| 2023 | 1,251 |
| 2024 | 1,027 |
| 2025 | 998 |
| 2026 | 1,110 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,040,101 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| heparin-induced thrombocytopeniaSignal | 1,293 | 531.8 | 500.2 | 505,159 |
| thrombosisSignal | 458 | 8.6 | 7.8 | 3,044 |
| pulmonary embolismSignal | 519 | 8.2 | 7.5 | 3,276 |
| sepsisSignal | 503 | 6.8 | 6.2 | 2,471 |
| thrombocytopeniaSignal | 479 | 6.4 | 5.9 | 2,194 |
| drug hypersensitivitySignal | 643 | 5.0 | 4.6 | 2,056 |
| hypotensionSignal | 571 | 4.3 | 3.9 | 1,435 |
| anaemiaSignal | 488 | 3.8 | 3.5 | 1,027 |
| abdominal painSignal | 483 | 3.1 | 2.8 | 696 |
| pyrexiaSignal | 499 | 2.2 | 2.0 | 314 |
| vomiting | 620 | 2.0 | 1.8 | 303 |
| dyspnoea | 558 | 1.5 | 1.4 | 87 |
| nausea | 754 | 1.4 | 1.3 | 99 |
| off label use | 787 | 1.3 | 1.3 | 72 |
| drug ineffective | 1,043 | 1.2 | 1.1 | 32 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.